Glucagon-like peptid-1 in obese and diabetic patients after bariatric interventions

Abstract

The relationship between the level of glucagon-like peptide-1 and repeated weight gain was evaluated in 31 patients suffering from grade II–III obesity and type 2 diabetes mellitus after bariatric interventions for 3 years. It was found that the level of stimulated glucagon-like peptide-1 significantly increased by the third day after sleeve gastroplasty and gastroschunt compared to the initial parameters (p = 0.001 for obese patients; p = 0.000 for obese patients and diabetes mellitus). In the plateau phase (body weight retention) after bariatric intervention, the level of stimulated glucagon-like peptide-1 in obese patients and patients suffering from obesity in combination with diabetes mellitus did not significantly differ from the indicators of healthy individuals. There was no association between the level of glucagon-like peptide-1 and repeated weight gain. This may be due to the limited contribution of glucagon-like peptide-1 to body weight dynamics after bariatric interventions and the predominance of patient compliance. Thus, the level of stimulated glucagon-like peptide-1 at baseline, on the third day and in the plateau phase after bariatric intervention was not associated with the value of repeated weight gain.

Keywords

obesity / glucagon-like peptide-1 / bariatric surgery / weight regain / the glycemic profile and insulin resistance

References

[1] Himpens J., Ramos A., Welbourn R., et al. Fourth IFSO Global Registry Report 2018. Dendrite Clinical Systems Ltd, Henley-on-Thames, RG9 1AY, UKISBN978-0-9929942-7-3; 2018.

[2] Himpens J, Ramos A, Welbourn R, et al. Fourth IFSO Global Registry Report 2018. Dendrite Clinical Systems Ltd, Henley-on-Thames, RG9 1AY, UKISBN978-0-9929942-7-3; 2018.

[3] Angrisani L., Santonicola A., Iovino P., et al. Bariatric surgery worldwide 2013 // Obes Surg. 2015. Vol. 25. P. 1822–32.

[4] Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery worldwide 2013. Obes Surg. 2015;25:1822–32.

[5] Sridharan K., Kalayarasan R., Kamalanathan S., et al. Change in insulin resistance, beta cell function, glucagon-like peptide-1 and calcitonin levels two weeks after bariatric surgery// Diabetes Metab Syndr. 2019. Vol. 13, No. 3. P. 2142–2147. doi: 10.1016/j.dsx.2019.05.002

[6] Sridharan K, Kalayarasan R, Kamalanathan S, et al. Change in insulin resistance, beta cell function, glucagon-like peptide-1 and calcitonin levels two weeks after bariatric surgery. Diabetes Metab Syndr. 2019;13(3):2142-2147. doi: 10.1016/j.dsx.2019.05.002

[7] Muñoz J.S., Rodríguez D., Morante J.J. Diurnal rhythms of plasma GLP-1 levels in normal and overweight/obese subjects: lack of effect of weight loss // J Physiol Biochem. 2015. Vol. 71, No. 1. P. 17–28. doi: 10.1007/s13105-014-0375-7

[8] Muñoz JS, Rodríguez D, Morante JJ. Diurnal rhythms of plasma GLP-1 levels in normal and overweight/obese subjects: lack of effect of weight loss. J Physiol Biochem. 2015;71(1):17–28. doi: 10.1007/s13105-014-0375-7

[9] Courcoulas et al, Seven-YearWeight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study // JAMA Surg. 2018. Vol. 153, No. 5. P. 427–434.

[10] Courcoulas et al, Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study, JAMA Surg. 2018;153(5):427–434.

[11] Monaco-Ferreira D.V., Leandro-Merhi V.A. Weight Regain 10 Years After Roux-en-Y Gastric Bypass // Obes Surg. 2017 May. Vol. 27, No. 5. P. 1137–1144. doi: 10.1007/s11695-016-2426-3

[12] Monaco-Ferreira DV, Leandro-Merhi VA. Weight Regain 10 Years After Roux-en-Y Gastric Bypass. Obes Surg. 2017;27(5):1137–1144. doi: 10.1007/s11695-016-2426-3.

[13] Brethauer S.A., Kim J., El Chaar M., et al. Standardized outcomes reporting in metabolic and bariatric surgery // Obes Surg. 2015. Vol. 25, No. 4. P. 587–606. doi: 10.1007/s11695-015-1645-3

[14] Brethauer SA, Kim J, El Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Obes Surg. 2015;25(4):587–606. doi: 10.1007/s11695-015-1645-3

[15] Santo M.A., Riccioppo D., Pajecki D., et al. Weight Regain After Gastric Bypass: Influence of Gut Hormones // Obes Surg. 2016. Vol. 26, No. 5. P. 919-925. doi: 10.1007/s11695-015-1908-z

[16] Santo MA, Riccioppo D, Pajecki D, et al. Weight Regain After Gastric Bypass: Influence of Gut Hormones. Obes Surg. 2016;26(5):919–925. doi: 10.1007/s11695-015-1908-z

[17] Gagnon J., Baggio L.L., Drucker D.J., et al. Ghrelin Is a Novel Regulator of GLP-1 Secretion // Diabetes. 2015. Vol. 64, No. 5. P. 1513–1521.doi: 10.2337/db14-1176

[18] Gagnon J, Baggio LL, Drucker DJ, et al. Ghrelin Is a Novel Regulator of GLP-1 Secretion. Diabetes. 2015;64(5):1513–1521.doi: 10.2337/db14-1176

[19] Jirapinyo P., Jin D.X., Qazi T., Mishra N., et al. A Meta-Analysis of GLP-1 After Roux-En-Y Gastric Bypass: Impact of Surgical Technique and Measurement Strateg // Obes Surg. 2018. Vol. 28, No. 3. P. 615–626. doi: 10.1007/s11695-017-2913-1

[20] Jirapinyo P, Jin DX, Qazi T, Mishra N, et al. A Meta-Analysis of GLP-1 After Roux-En-Y Gastric Bypass: Impact of Surgical Technique and Measurement Strategy. Obes Surg. 2018;28(3):615–626. doi: 10.1007/s11695-017-2913-1

RIGHTS & PERMISSIONS

Volkova A.R., Semikova G.V., Mozgunova V.S., Maltseva M.N., Bondarenko V.L., Katysheva N.S.